IART · Integra LifeSciences Holdings Corporation · Stock research

Current Thesis

The shelf that defined this name since June is gone. Integra closed at $16.74 on 2026-08-21 — a Friday, so a weekly close beneath the ~$17 floor that the post-Argus advance built above the ~$17.43 consensus and the old $17.83 high. Two weeks earlier the last completed close was $17.25 with RSI(14) at 40.7; the reading is now 36.8 and the stock sits 15.7% below the $19.85 52-week high. The three-month price change has compressed to +10.9% from +23.9% as measured on 2026-08-07.

What broke is the re-rating, not the P&L. The 2026-07-29 Q2 print delivered adjusted EPS $0.56 against $0.48 consensus and returned GAAP net income to $4.48M from a $484.07M year-ago loss. The tape gave the beat back inside three weeks. Every Hold-grade mark from the July coverage cluster — Citi Neutral $19 (2026-07-08), BMO Market Perform $19 (2026-07-09), UBS Neutral $19 (2026-07-28), Wells Fargo Equal Weight $18 (2026-07-30) — now sits above price rather than beneath it, and the 2026-08-04 street average of $19.56 (range $14–$27) is a ceiling the stock is walking away from.

The narrative is dead for the distressed-to-fair re-rating leg. What dates it: the 2026-08-21 weekly close below the June structure; the 2026-07-29 EPS beat that failed to hold; the completion of the initiation cycle on 2026-07-30 with no rating action surfacing since. What survives is a value and floor argument on the reaffirmed FY26 adjusted-EPS guide of $2.40–$2.50 — a slower, less crowded proposition with no dated resolution before the Q3 print on the existing cadence.

Bullish and bearish views on Integra LifeSciences Holdings Corporation

The model's bull view on Integra LifeSciences Holdings Corporation (IART), in brief: Q2 2026 (2026-07-29): adjusted EPS $0.56 vs $0.48 consensus, above the company's own guide, on revenue of $418.761M vs $415.61M a year earlier (+0.8% reported). The bear view: Demand growth is absent for a second straight quarter: organic revenue +1.3% at Q1 (2026-05-05), flat year over year at Q2 (2026-07-29). Both cases follow in full.

Bull Case

• Q2 2026 (2026-07-29): adjusted EPS $0.56 vs $0.48 consensus, above the company's own guide, on revenue of $418.761M vs $415.61M a year earlier (+0.8% reported).
• GAAP profitability restored: net income $4.48M against a $484.07M net loss in the year-ago quarter; operating margin 9.6% vs 7.9%; adjusted EBITDA margin 18.7%.
• The earnings guide held while the revenue range was trimmed: FY26 adjusted EPS reaffirmed at $2.40–$2.50 on 2026-07-29, with the revenue reduction attributed to dollar strength rather than unit demand.
• Founder-era management is in the chair: Stuart Essig was named President and CEO effective 2026-05-01 (announced with Q1 on 2026-05-05), alongside Michael McBreen as chief commercial officer — the governance change that anchors the pivot.
• Remediation converting to product: management guided a controlled SurgiMend relaunch for Q4 2026 on the 2026-07-29 call.
• The street's own marks sit above the tape: average target $19.56 as of 2026-08-04, with the low end of the range at $14 and Argus's Buy $25 (2026-06-18) at the top.

Bear Case

• Demand growth is absent for a second straight quarter: organic revenue +1.3% at Q1 (2026-05-05), flat year over year at Q2 (2026-07-29).
• FY26 revenue guidance was cut on 2026-07-29 from $1.662B–$1.702B to $1.654B–$1.695B, placing the range under the $1.676B consensus mid.
• Q3 guidance brackets consensus without clearing it: adjusted EPS $0.53–$0.61 vs $0.56, sales $410M–$425M vs $418.1M.
• Earnings quality is policy-linked: the CFO cited an IEEPA tariff benefit inside adjusted EPS at both the 2026-05-05 and 2026-07-29 prints, and the adjusted and GAAP lines diverge materially.
• Coverage is Hold-heavy and complete: 3 buy / 7 hold / 2 sell per Benzinga's aggregation as of 2026-08-08; the four Neutral-grade marks all landed inside a 22-day window ending 2026-07-30, after the move.
• The compliance channel that caused the original collapse is unresolved history: an FDA warning letter dated 2024-12-19 cited quality-system findings at Mansfield MA, Plainsboro NJ and Princeton NJ, following the 2024-09-06 Duraform recall and the 2024-09-20 surgical patties and strips recall.

Setup & Price Structure

• Reference close $16.74 on 2026-08-21, 15.7% under the $19.85 52-week high, RSI(14) 36.8.
• The June structure has failed: price is below the ~$17 shelf, below the ~$17.43 consensus zone, and below the $17.83 prior high the June breakout cleared. A weekly close back above $17.83 is what would mark structural repair; nothing between $16.74 and there is defended by a dated event.
• Positioning observables, stated as observed: four Hold-grade initiations or target moves arrived 2026-07-08 through 2026-07-30, i.e. new coverage clustering into strength after a large advance; all four marks now sit above the tape; no rating action has surfaced since 2026-07-30; there is no earnings date inside the next 30 days; RSI at 36.8 with price under the shelf describes momentum decay with no squeeze mechanics — short-interest is not the driver here, the quarterly cadence is.
• The 2026-07-29 beat produced no sustained bid. That is the observable that separates this from a routine pullback inside an intact trend.

Catalyst Calendar (next 30 days)

• 2026-08-22 to 2026-09-21: no company-confirmed event. On the established cadence — Q1 on 2026-05-05, Q2 on 2026-07-29 — nothing scheduled falls inside the window.
• ~2026-10-28 (est.): Q3 2026 results. First read on whether organic growth moves off flat, whether the FY26 revenue range is trimmed a second time, and whether the tariff benefit inside adjusted EPS is characterised as recurring.
• ~2026-12-31 (est.): controlled SurgiMend relaunch, guided for Q4 2026 on the 2026-07-29 call.

What Would Change Our Mind

The June shelf has already given way, so the question is whether the break extends or repairs. Repair would look like a weekly close back above $17.83 — reclaiming the high the June breakout originally cleared — accompanied by organic growth off flat at the ~2026-10-28 Q3 print. Continuation of the break is defined by a weekly close below $16, which would complete the round-trip of the post-2026-06-18 Argus advance and leave price nearer the $14 low end of the 2026-08-04 target range than the $19.56 average. The fundamental clause that would independently confirm the downside read: a third consecutive quarter of flat-to-negative organic growth at Q3, an FY26 adjusted-EPS reset, or any of Citi, BMO, UBS or Wells Fargo marking down below $17. On the other side, a renewed 8-K or FDA action referencing recall, warning letter or production suspension would remove the turnaround premise regardless of where the multiple sits.

Correlation Notes

• Dollar sensitivity is explicit, not inferred: the FY26 revenue cut on 2026-07-29 was attributed to a stronger US dollar, which links reported revenue to DXY direction over the September quarter.
• Trade-policy channel: adjusted EPS carries an IEEPA tariff benefit per CFO commentary on 2026-05-05 and 2026-07-29, so tariff-regime changes hit the earnings line before they hit the revenue line.
• Reimbursement channel: Tissue Technologies printed flat at Q2 with management citing reimbursement pressure, tying the SurgiMend recovery to skin-substitute payment policy rather than to surgical volumes.
• Peer group: small- and mid-cap neurosurgery and regenerative device names move together on multiple and rate shifts; the company-specific variance here comes from quality-system remediation and supply reliability, which has no peer beta.